肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

BRCA1/2突变的年轻患者是否适宜保乳手术？

2021-07-07 MedSci原创 MedSci原创

乳腺癌
关注

《梅斯直播课：3天乳腺癌诊疗训练营》06.25-年轻乳腺癌的治疗要点及生育管理

《梅斯直播课：3天乳腺癌诊疗训练营》
06.25-年轻乳腺癌的治疗要点及生育管理
回答问题4：BRCA1/2突变的年轻患者是否适宜保乳手术？

 

欢迎点赞、评论、分享

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1015285, encodeId=e355101528537, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9135543621, createdName=ms8000001555059050, createdTime=Tue Sep 07 09:27:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423320, encodeId=09b4142332080, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518985, encodeId=5716151898555, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3688, encryptionId=da4e368832, topicName=BRCA1/2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ce11226326, createdName=fangcong, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525706, encodeId=6caf1525e06c3, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594084, encodeId=0f7a159408418, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621453, encodeId=d1f8162145303, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3689, encryptionId=1c3b36890d, topicName=BRCA1/2突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=085920261380, createdName=jiyangfei, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997240, encodeId=0d1c99e24039, content=根据病灶情况而定吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Wed Jul 07 16:31:04 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-09-07 ms8000001555059050

    学习啦

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1015285, encodeId=e355101528537, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9135543621, createdName=ms8000001555059050, createdTime=Tue Sep 07 09:27:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423320, encodeId=09b4142332080, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518985, encodeId=5716151898555, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3688, encryptionId=da4e368832, topicName=BRCA1/2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ce11226326, createdName=fangcong, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525706, encodeId=6caf1525e06c3, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594084, encodeId=0f7a159408418, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621453, encodeId=d1f8162145303, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3689, encryptionId=1c3b36890d, topicName=BRCA1/2突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=085920261380, createdName=jiyangfei, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997240, encodeId=0d1c99e24039, content=根据病灶情况而定吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Wed Jul 07 16:31:04 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-09 caobinglei8080

    #BRCA1#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1015285, encodeId=e355101528537, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9135543621, createdName=ms8000001555059050, createdTime=Tue Sep 07 09:27:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423320, encodeId=09b4142332080, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518985, encodeId=5716151898555, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3688, encryptionId=da4e368832, topicName=BRCA1/2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ce11226326, createdName=fangcong, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525706, encodeId=6caf1525e06c3, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594084, encodeId=0f7a159408418, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621453, encodeId=d1f8162145303, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3689, encryptionId=1c3b36890d, topicName=BRCA1/2突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=085920261380, createdName=jiyangfei, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997240, encodeId=0d1c99e24039, content=根据病灶情况而定吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Wed Jul 07 16:31:04 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-09 fangcong

    #BRCA1/2#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1015285, encodeId=e355101528537, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9135543621, createdName=ms8000001555059050, createdTime=Tue Sep 07 09:27:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423320, encodeId=09b4142332080, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518985, encodeId=5716151898555, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3688, encryptionId=da4e368832, topicName=BRCA1/2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ce11226326, createdName=fangcong, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525706, encodeId=6caf1525e06c3, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594084, encodeId=0f7a159408418, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621453, encodeId=d1f8162145303, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3689, encryptionId=1c3b36890d, topicName=BRCA1/2突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=085920261380, createdName=jiyangfei, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997240, encodeId=0d1c99e24039, content=根据病灶情况而定吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Wed Jul 07 16:31:04 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-09 minzju5056

    #年轻患者#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1015285, encodeId=e355101528537, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9135543621, createdName=ms8000001555059050, createdTime=Tue Sep 07 09:27:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423320, encodeId=09b4142332080, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518985, encodeId=5716151898555, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3688, encryptionId=da4e368832, topicName=BRCA1/2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ce11226326, createdName=fangcong, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525706, encodeId=6caf1525e06c3, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594084, encodeId=0f7a159408418, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621453, encodeId=d1f8162145303, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3689, encryptionId=1c3b36890d, topicName=BRCA1/2突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=085920261380, createdName=jiyangfei, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997240, encodeId=0d1c99e24039, content=根据病灶情况而定吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Wed Jul 07 16:31:04 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-09 智智灵药

    #BRCA#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1015285, encodeId=e355101528537, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9135543621, createdName=ms8000001555059050, createdTime=Tue Sep 07 09:27:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423320, encodeId=09b4142332080, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518985, encodeId=5716151898555, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3688, encryptionId=da4e368832, topicName=BRCA1/2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ce11226326, createdName=fangcong, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525706, encodeId=6caf1525e06c3, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594084, encodeId=0f7a159408418, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621453, encodeId=d1f8162145303, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3689, encryptionId=1c3b36890d, topicName=BRCA1/2突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=085920261380, createdName=jiyangfei, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997240, encodeId=0d1c99e24039, content=根据病灶情况而定吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Wed Jul 07 16:31:04 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-09 jiyangfei

    #BRCA1/2突变#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1015285, encodeId=e355101528537, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9135543621, createdName=ms8000001555059050, createdTime=Tue Sep 07 09:27:50 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423320, encodeId=09b4142332080, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518985, encodeId=5716151898555, content=<a href='/topic/show?id=da4e368832' target=_blank style='color:#2F92EE;'>#BRCA1/2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3688, encryptionId=da4e368832, topicName=BRCA1/2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63ce11226326, createdName=fangcong, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525706, encodeId=6caf1525e06c3, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594084, encodeId=0f7a159408418, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621453, encodeId=d1f8162145303, content=<a href='/topic/show?id=1c3b36890d' target=_blank style='color:#2F92EE;'>#BRCA1/2突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3689, encryptionId=1c3b36890d, topicName=BRCA1/2突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=085920261380, createdName=jiyangfei, createdTime=Fri Jul 09 06:05:57 CST 2021, time=2021-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=997240, encodeId=0d1c99e24039, content=根据病灶情况而定吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Wed Jul 07 16:31:04 CST 2021, time=2021-07-07, status=1, ipAttribution=)]
    2021-07-07 1244c0ebm28暂无昵称

    根据病灶情况而定吧

    0

相关资讯

《梅斯直播课：3天乳腺癌诊疗训练营》2021.7.1问题回答9

《梅斯直播课：3天乳腺癌诊疗训练营》2021.7.1问题回答9

年轻乳腺癌的肿瘤特征是什么？复发风险和预后有何特点？

《梅斯直播课：3天乳腺癌诊疗训练营》06.25-年轻乳腺癌的治疗要点及生育管理

乳腺癌复查时间

《梅斯直播课：3天乳腺癌诊疗训练营》

年轻乳腺癌的治疗要点及生育管理：乳腺癌根治术术后患侧不适

《梅斯直播课：3天乳腺癌诊疗训练营》

乳腺粘液性癌术后治疗

《梅斯直播课：3天乳腺癌诊疗训练营》问题回答11：乳腺粘液性癌病例分析

年轻乳腺癌应选择乳房切除术还是保乳手术？

《梅斯直播课：3天乳腺癌诊疗训练营》06.25-年轻乳腺癌的治疗要点及生育管理

拓展阅读

绘真约大咖 | 张万生教授：BRCA1/2突变检测指导前列腺癌靶向治疗、评估遗传风险和预后

在mCRPC患者中，BRCA1/2基因突变是重要的可用药靶点，也是国内外指南和专家共识明确推荐的检测基因。

J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险

在输卵管卵巢切除术时患有浆液性输卵管上皮内癌的BRCA1/2致病性变异携带者，随后发生腹膜癌的风险随着时间的推移而升高

Nat Commun：BRCA1/BRCA2突变携带者的乳腺癌发病风险研究

乳腺癌（BC）作为全球女性中最常见的癌症，BC家族史是该病最重要的危险因素之一。

Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响

BRCA1和BRCA2在DNA修复中起核心作用。因此，携带胚系(g)BRCA1/2突变(m)的患者接受化疗治疗后，发生血液性毒性的风险可能更高。

Lancet Oncol：奥拉帕尼片剂可用于铂敏感、复发性卵巢癌及BRCA1/2突变(SOLO2/ENGOT-Ov21/)患者的维持治疗

奥拉帕尼是一种多聚(ADP-核糖)聚合酶(PARP)抑制剂。在第2期的研究（奥拉帕尼胶囊）中，其对铂敏感、复发性高度浆液性卵巢癌患者有疗效。近日，在医学权威杂志Lancet上面发表了一篇研究文章，该文章旨在探讨奥拉帕尼片剂是否可用于BRCA1或BRCA2(BRCA2)突变的治疗。

JCO:口服避孕药不降低BRCA1/2突变携带者的卵巢癌及乳腺癌风险

口服避孕药与卵巢癌关系 研究要点： 本研究针对因BRCA1/2突变或有较强家族史而存在卵巢癌或乳腺癌风险增加的女性，评价了口服避孕药对两种肿瘤的相关风险；针对BRCA1/2突变携带者总体的荟萃分析表明，口服避孕药与卵巢癌间存在负向关联，但与乳腺癌间并无统计学意义的显著关联；BRCA1及BRCA2突变也有类似结果。 在2013年10月21日在线出版的《临床肿瘤学杂志》(Jour